NCT01462669 - Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2012

Primary Completion Date

June 27, 2012

Study Completion Date

June 27, 2012

Conditions

Epilepsy

Interventions

DRUG

50mg Ezogabine/retigabine

A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

DRUG

100mg Ezogabine/retigabine

A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

DRUG

200mg Ezogabine/retigabine

A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

DRUG

400mg Ezogabine/retigabine

A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state

Trial Locations (1)

GSK Investigational Site, Taipei